Study Reports Potential Target And Compounds To Slow Development Of Alzheimer’s Disease
Researchers at LSU Health New Orleans Neuroscience Center of Excellence and Karolinska Institutet have discovered a potential biomarker for Alzheimer’s disease diagnosis that may also serve as a therapeutic target. Examining cerebrospinal fluid samples from patients with cognitive impairment ranging from subjective impairment to a diagnosis of Alzheimer’s disease, they found a shift in the profile of specialized lipid mediators from pro-resolving to pro-inflammatory. The results of the exploratory study are published in the Springer journal, Cellular and Molecular Neurobiology.
Specialized lipid mediators are bioactive compounds composed of polyunsaturated fatty acids like DHA and EPA. They are signaling molecules that regulate a wide range of cellular responses including cell growth and death, as well as infection and inflammation. Specialized lipid mediators have unique properties and roles in inflammation. Pro-inflammatory lipid mediators promote inflammation, and pro-resolving lipid mediators resolve inflammation.
It takes several years or more for Alzheimer’s disease (AD) to develop into dementia, and neuroinflammation is a key early contributor. During that time, subjective cognitive impairment (SCI) and mild cognitive impairment (MCI) can be used as intermediary diagnoses of increasing severity. The population of this study consisted of 136 participants – 53 with SCI, 43 with MCI and 40 with an Alzheimer’s disease diagnosis. The researchers assessed 22 lipids in samples of the participants’ cerebrospinal fluid (CSF), including pro-resolving lipid mediators, pro-inflammatory lipid mediators, prostaglandins, their fatty acid precursors and intermediate derivatives. Neuroprotection D1 (NPD1), discovered by the Bazan lab, is one the pro-resolving lipid mediators studied.
The research team found that levels of pro-resolving lipid mediators were correlated with severity of cognition impairment –the greater the severity, the lower the levels of the lipid mediators that resolve inflammation. They also found a relationship between cognition impairment severity and pro-inflammatory lipid mediators – the greater the degree of cognition impairment, the higher the levels of the lipid mediators that promote inflammation.
“Based on these findings, we are expanding our work to brain cell-specific targets, besides neurons, astrocytes and microglia, as well as additional novel protective signals, which would allow us to explore slowing down AD onset,” says Nicolas Bazan, MD, PhD, Boyd Professor and Director of LSU Health New Orleans Neuroscience Center of Excellence. “For this purpose, we have set up 10-x genomics to decipher not only the genes but also epigenomics engaged in early disease states. Since the CSF lipidome changes were closely correlated with detailed clinical and radiological AD patient status, we believe that the studied events are revealing novel essential mechanisms of brain health. A uniqueness of our approach is that we have discovered mechanisms and, more importantly, molecules that target those mechanisms and could became therapeutics.”